Memphis' David Pellom out five weeks after knee surgery
Memphis will start the season shorthanded in the frontcourt, as graduate transfer David Pellom will miss the next five weeks after knee surgery.
Memphis forward David Pellom underwent arthroscopic surgery on his left knee on Thursday, the school announced.
Pellom is expected to miss the next five weeks.
“It was a simply and minor procedure, and we expect David back in no time,” coach Josh Pastner said in a statement.
Pellom, a 6-foot-7 forward, transferred into the program from George Washington in the spring. He averaged 10.4 points and 6.1 rebounds two seasons ago with the Colonials, but sat out 2012-13 after injuring his wrist while recovering from meniscus surgery on his left knee. Pellom was able to play immediately as a graduate student.
With Pellom on the mend, Pastner will lean on a host of youngsters to pick up the frontcourt minutes. Freshmen Nick King and Kuran Iverson can play both forward positions, while classmate Austin Nichols could see increased minutes inside. Sophomore forward Shaq Goodwin will be the elder statesman down low, after averaging 7.4 points and 4.4 rebounds last season.
Memphis hosts Christian Brothers in an exhibition game Friday.
The Tigers play Austin Peay next week.
CBS Sports HQ Daily Newsletter
Get the best highlights and stories - yeah, just the good stuff handpicked by our team to start your day.
Thanks for signing up!
Keep an eye on your inbox for the latest sports news.
There was an error processing your subscription.
It's back! The most definitive list of the top talent in the sport is here
Mike Kryzewski claimed the things brought up in this trial were a 'blip,' but now one of his...
Michigan State, Purdue and LSU should all feel great about their trusty ball-handlers as the...
The Blue Devils Hall of Famer believes the corruption trial is a 'blip'
The Kansas coach wanted Adidas' help, in part, because he believed Nike was helping Duke and...
The government's case has had its skeptics, but from inside the courtroom this trial very much...